Blood markers for depression and suicidal thoughts in teenagers
Studies blood markers and standard depression treatment in young people with depression and suicidal thoughts.
Plain-language title generated from the registry record
Registry title: Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
Key facts
- Where
- Birmingham and Huntsville, United StatesSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 24 years old?
Source: NCT05437588, who can take part
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesTaking people
- UAB Huntsville Regional Medical CampusHuntsville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT05437588
- Record updated
- 13 July 2026
- Original description
This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.Read full original descriptionShow less
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.
Inclusion: All participants:; Physically healthy; willing and able to provide informed consent (if under 18 also parent or guardian consent); MDD participants:; A definite diagnosis of DSM-5; a Children's Depression Rating Scale-Revised (CDRS-R) score >=30. Suicidal ideation participants: Columbia Suicide Severity Rating Scale (C-SSRS) score >=4 rated over the last two weeks; Suicide attempt group:; Participants will have had an attempt in the previous two weeks that is serious enough to require medical attention and shows evidence of at least a medium level of intent on the Suicide Intent Scale; Non-psychiatric controls:; No history of any major mental illness (excluding specific phobia) or substance use disorder.
Exclusion: Exclusion criteria:; Pregnancy or lactation; post-partum state (being within 2 months of delivery or miscarriage); homicide risk as determined by clinical interview; any of the following DSM-V diagnoses or categories: a) a lifetime history of psychotic disorder; b) alcohol or drug use disorder (except nicotine/caffeine) within the last month; the use of any hallucinogen (except cannabis), including phencyclidine in the last month; c) bipolar disorder; d) pervasive developmental disorder; e) cognitive disorder; f) DSM-5 paranoid, schizoid, or schizotypal personality disorders (PDs) (participants with other PDs will be allowed as long as MDD criteria are met); g) anorexia nervosa; recent myocardial infarction or unstable angina, active neoplasm in the past 6 months, immunosuppressive or corticosteroid therapy within the last month, chemotherapy, and head injury or loss of consciousness in the past 6 months; use of hallucinogens (except for cannabis), methamphetamine, or cocaine in the last 2 weeks.